Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz419.007
Abstract: Abstract Background The studies on hypo-fractionation for GBM showed 5-12 months median overall survivals not inferior to standard fractionation protocols. We aimed to describe the feasibility of extreme hypo fractionation combined with temozolamide for newly… read more here.
Keywords: five fractions; newly diagnosed; gbm; combined temozolamide ... See more keywords